Search - tctmd.com

Displaying 61 - 80 of 88

Sort: Relevancy | Date

Presentation ARCH 2022

First Things First – Pharmacotherapy for HFrEF

Presenter: Georges Chahoud

April 23, 2022

Presentation ARCH 2022

Candidate Selection for Advanced Heart Failure Therapies: 2022

Presenter: Gregory Ewald

April 23, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

Presentation THT 2022

Design and Rationale of the CORCINCH-HF pivotal study

Presenter: Ulrich Jorde

February 01, 2022

Presentation THT 2022

12-Month Outcomes for the AccuCinch System in HFrEF

Presenter: Nadira Hamid

February 01, 2022

Presentation THT 2022

From Access to Anchors: The AccuCinch Ventricular Restoration System

Presenter: Mohamed Latib

February 01, 2022

Presentation THT 2022

Reverse Remodeling in Heart Failure

Presenter: Daniel Burkhoff

February 01, 2022

Presentation Controversies and Advances 2021

SGLT2 Inhibitors and Heart Failure

Presenter: Michelle M. Kittleson

December 03, 2021

Presentation Controversies and Advances 2021

Role of Digoxin in Heart Failure and Atrial Fibrillation

Presenter: Michelle M. Kittleson

December 03, 2021

Presentation Controversies and Advances 2021

In Defense of Digoxin

Presenter: John Mandrola

December 03, 2021

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

Presentation

RAS Inhibition Following TAVR

July 29, 2019

Presentation Controversies and Advances 2018

Pharmacogenomics in Cardiovascular Medicine

Presenter: Clyde W. Yancy

November 16, 2018

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

Presentation

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

April 17, 2018

Presentation TCT 2017

Beyond Heparin: When and How to Escalate Therapy for Acute PE (Lytics, Catheter-Based, Surgery)

Presenter: Peter P. Monteleone, Thomas M. Tu, Jay S. Giri

November 01, 2017

Presentation TCT 2017

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Presenter: James E. Udelson

November 01, 2017

Advertisement

First Things First – Pharmacotherapy for HFrEF

Candidate Selection for Advanced Heart Failure Therapies: 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Design and Rationale of the CORCINCH-HF pivotal study

12-Month Outcomes for the AccuCinch System in HFrEF

From Access to Anchors: The AccuCinch Ventricular Restoration System

Reverse Remodeling in Heart Failure

SGLT2 Inhibitors and Heart Failure

Role of Digoxin in Heart Failure and Atrial Fibrillation

In Defense of Digoxin

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

RAS Inhibition Following TAVR

Pharmacogenomics in Cardiovascular Medicine

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

Beyond Heparin: When and How to Escalate Therapy for Acute PE (Lytics, Catheter-Based, Surgery)

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content